Skip to Content

Generic Cyklokapron Availability

Cyklokapron is a brand name of tranexamic acid, approved by the FDA in the following formulation(s):

CYKLOKAPRON (tranexamic acid - injectable;injection)

  • Manufacturer: PHARMACIA AND UPJOHN
    Approval date: December 30, 1986
    Strength(s): 100MG/ML [RLD] [AP]

CYKLOKAPRON (tranexamic acid - tablet;oral)

  • Manufacturer: PHARMACIA AND UPJOHN
    Approval date: December 30, 1986
    Strength(s): 500MG

Has a generic version of Cyklokapron been approved?

Yes. The following products are equivalent to Cyklokapron:

tranexamic acid injectable;injection

  • Manufacturer: ACIC FINE CHEMS
    Approval date: February 11, 2014
    Strength(s): 100MG/ML [AP]
  • Manufacturer: AKORN
    Approval date: November 17, 2011
    Strength(s): 100MG/ML [AP]
  • Manufacturer: AKORN
    Approval date: June 9, 2016
    Strength(s): 100MG/ML [AP]
  • Manufacturer: AMNEAL PHARMS CO
    Approval date: February 28, 2017
    Strength(s): 100MG/ML [AP]
  • Manufacturer: AUROBINDO PHARMA LTD
    Approval date: January 14, 2016
    Strength(s): 100MG/ML [AP]
  • Manufacturer: EMCURE PHARMS LTD
    Approval date: August 12, 2014
    Strength(s): 100MG/ML [AP]
  • Manufacturer: FRESENIUS KABI USA
    Approval date: March 2, 2012
    Strength(s): 100MG/ML [AP]
  • Manufacturer: GLAND PHARMA LTD
    Approval date: February 13, 2017
    Strength(s): 100MG/ML [AP]
  • Manufacturer: LUITPOLD
    Approval date: August 10, 2011
    Strength(s): 100MG/ML [AP]
  • Manufacturer: MICRO LABS
    Approval date: June 27, 2017
    Strength(s): 100MG/ML [AP]
    Approval date: November 3, 2011
    Strength(s): 100MG/ML [AP]
  • Manufacturer: NORTH CREEK PHARMS
    Approval date: February 25, 2016
    Strength(s): 100MG/ML [AP]
  • Manufacturer: X-GEN PHARMS INC
    Approval date: June 14, 2013
    Strength(s): 100MG/ML [AP]
  • Manufacturer: ZYDUS PHARMS USA INC
    Approval date: July 17, 2017
    Strength(s): 100MG/ML [AP]

Note: No generic formulation of the following product is available.

  • tranexamic acid - tablet;oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cyklokapron. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
APInjectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.